Deramiocel was turned down by the FDA for a second time on 20 November 2026, and the agency said in public that the main trial’s data are unreliable. This brief explains what the trial measured, how its main result moved from P = 0.24 to P = 0.029, and what readers can check for themselves.
Deramiocel is a cell therapy for Duchenne muscular dystrophy made by Capricor Therapeutics. On 20 November 2026 the FDA declined to approve it, two days before its deadline. Capricor announced the Complete Response Letter that evening, and the FDA published a statement of its own. A Complete Response Letter, or CRL, is what the agency sends when it finishes a review and cannot approve the application as filed.
The two documents describe the same letter in very different terms. Capricor says the FDA found the evidence insufficient and cited other clinical deficiencies. The FDA says its inspectors found serious data integrity violations in HOPE-3, the phase 3 trial behind the application. In the agency’s words, the trial failed “to meet its pre-specified primary and secondary efficacy endpoints”.
Capricor and a paper in The Lancet report the opposite, a primary endpoint met with a P value of 0.029. Both claims trace back to the same 106 patients, and the FDA’s own briefing document shows how. Under the analysis plan written before the trial began, the P value was 0.24. In the final analysis it was 0.029, and the handling of two placebo patients explains much of the difference. The sections below walk through it one step at a time.
01What deramiocel is, and what Duchenne does to muscle
Duchenne muscular dystrophy, or DMD, is a genetic disease that affects mostly boys. A fault in the gene for dystrophin, a protein that protects muscle fibres, leaves muscle easy to damage. Each round of damage brings inflammation, and over the years scar tissue replaces working muscle. Boys usually lose the ability to walk first and strength in the arms later. The heart is a muscle too, so it weakens as well. Capricor’s briefing document for the FDA calls this heart damage, known as cardiomyopathy, the leading cause of death in the disease.
Deramiocel, also called CAP-1002, takes a different route from the gene-based medicines for DMD. It is made of cardiosphere-derived cells, which are grown from donated human hearts. The term “allogeneic” means the cells come from a donor, so every patient receives the same kind of product. Capricor describes them as neither stem cells nor genetically modified. Patients receive 150 million cells through a vein every three months.
The therapy does not replace dystrophin. Its aim is to calm inflammation and slow scarring, so that muscle is lost more slowly. Section 06 explains how that is thought to happen and how strong the evidence is.
How the application reached this point
A Biologics License Application, or BLA, is the file a company submits to the FDA to sell a biological medicine. Capricor’s first BLA rested on HOPE-2, a phase 2 trial of 20 patients, and it drew a CRL in July 2025. The company resubmitted with HOPE-3, and that second attempt is the one the FDA has now turned down. Capricor’s quarterly report, the FDA’s briefing document and the trial’s registry record supply the dates below.
The two rejections are 499 days apart (computed). Over that period the evidence grew from 20 randomised patients to 106, and the FDA’s stated objection hardened. In 2025 the agency wanted more data. In 2026 it says the data it received cannot be relied on.
02The deramiocel CRL: what the FDA decided on 20 November
The decision reached the public as two documents on one evening. They are easier to understand side by side, because each leaves out what the other stresses.
The inspection behind the FDA’s statement was run by its Bioresearch Monitoring programme, known as BIMO. BIMO inspectors visit trial sites, sponsors and contractors. Their job is to check that a study was run as its protocol said and that its data can be trusted. According to a Capricor Form 8-K, inspectors were at the company from 6 to 20 July 2026.
An inspection ends with a Form 483 if the inspectors have concerns, and the form lists them as numbered observations. Capricor’s quarterly report says its Form 483 carried one observation. It covered operating procedures, documentation, oversight of vendors and the timing of audit reports. The company told investors the observation did not affect the integrity of the data and that it had sent its response.
Four months later the FDA describes the findings in far stronger language. Its statement lists unauthorised changes to the statistical analysis plan made after the fact, violations of the study’s blinding procedures, and further protocol violations. It says these problems cannot be repaired afterwards and that they make the HOPE-3 data unreliable. The agency adds that the data could not support approval even if the question of clinical meaning were settled.
The statement also mentions a second letter sent the same day, which it calls a Regulatory Responsibility Letter. That letter deals with the inspection findings, and Capricor will have the chance to answer it. The statement does not explain the term any further.
Capricor’s release answers none of this directly, because it does not mention the inspection. Chief executive Linda Marbán is quoted in it: “We stand behind the rigor of our clinical program”. The company says it is studying the letter and will discuss next steps on a call on Monday 23 November at 8:30 a.m. Eastern time.
03HOPE-3 trial results: one deramiocel trial, two answers
HOPE-3 enrolled boys and young men aged 10 and over with DMD at 20 hospitals, all in the United States, according to its registry record. It screened 139 patients and randomised 106, with 54 assigned to deramiocel and 52 to placebo. Each patient was due four infusions over 12 months. The trial was double-blind, which means neither the patients nor the staff scoring them knew who received which infusion. About 85% of the patients could no longer walk.
With walking already lost, the trial measured the arms. Its primary endpoint, the one result a trial is built to test, used the Performance of the Upper Limb scale, version 2.0. On PUL 2.0 a physiotherapist scores tasks at the shoulder, elbow, wrist and hand, and a higher total means better function. In DMD the score falls with time. So a therapy succeeds on this scale if the score falls more slowly than it does on placebo.
The key secondary endpoint was left ventricular ejection fraction, or LVEF. This is the share of blood that the heart’s main pumping chamber pushes out with each beat, measured here by cardiac MRI. A falling LVEF is a standard sign that cardiomyopathy is advancing.
One more number is needed before the results. The original plan sized the trial to detect a difference of 1.5 points in the PUL 2.0 change between the arms. That is the yardstick for the first analysis.
Under the plan written in July 2022, patients on deramiocel lost 1.73 points over the year and patients on placebo lost 2.39. The gap of 0.66 points is 44% of what the trial was designed to find (computed), and its P value was 0.24. A P value estimates how often a gap this large would appear by chance if the therapy did nothing. By convention a trial counts as positive only when that figure is below 0.05.
The final analysis measured each patient’s change as a percentage of his own starting score. On that measure the decline was 3.86% on deramiocel and 8.41% on placebo, and the gap of 4.55 percentage points had a P value of 0.029. This is the result published in The Lancet (McDonald et al., via PubMed). It is also the basis of Capricor’s statement that the therapy slowed the loss of arm function by 54%.
Slowing under the first plan (2.39 − 1.73) ÷ 2.39 = 28%, at P = 0.24
Decline in the final analysis 8.41% on placebo, 3.86% on treatment
Slowing in the final analysis (8.41 − 3.86) ÷ 8.41 = 54%, at P = 0.029
Both sets of numbers lean towards deramiocel, and neither shows harm on the arm scale. The disagreement is over which result is the trial’s real answer, the smaller one that missed or the larger one that passed. To see why they differ, it helps to follow the P value through each version of the plan.
The FDA’s briefing document reruns the primary endpoint under each version, and Fig 1 plots the outcome. Switching the measure from points to percentages changed little, since 0.24 became 0.26. The third version of the plan, applied to the data as observed, gave 0.21. Only when two placebo patients were handled the way that version specified did the result cross 0.05.
One of those patients withdrew from the trial after an adverse event. Under the plan he was assigned the worst score recorded in any patient at each visit he missed. Another took a medicine the protocol prohibited, and his results from months 6, 9 and 12 were removed. With both rules applied, the P value came to 0.045. Capricor’s study report then added a term for slowly progressing patients, which brought it to 0.029.
Rules like these are common in clinical trials, and regulators accept them when they are fixed before anyone can see their effect. The first rule entered the plan in December 2023, while patients were still being treated. The second entered on 24 November 2025, one day before the treatment codes were opened. Both made the placebo arm look worse. So the question of who could have known what, and when, carries the whole result.
04The statistical analysis plan: what changed in HOPE-3, and when
A statistical analysis plan, or SAP, is the document that fixes how a trial’s data will be analysed. It names the measure, the statistical model and the treatment of missing values. It is written before the results are known for a simple reason. With enough reasonable-looking choices, many datasets can be nudged across the 0.05 line. Fixing the choices in advance takes that freedom away.
Unblinding is the moment the sealed treatment codes are opened, so that analysts can see which patients received the therapy. Changes to a plan before that moment are normally accepted, because nobody can tell which way they will push the result. Changes made afterwards are called post hoc, and they carry far less weight.
HOPE-3’s plan went through at least five versions before unblinding. Versions 1.1, 1.5 and 1.7, written between July 2022 and December 2023, all kept the primary endpoint as the change in PUL 2.0 points. The last blinded visit took place on 18 June 2025. In July 2025, after the first CRL, Capricor drafted a protocol that made LVEF the primary endpoint. Its own briefing document records this and adds that the draft was never put into effect. At a Type A meeting in August the FDA asked that PUL 2.0 stay primary. A Type A meeting is one a company can request after a rejection to agree a way forward.
Version 2.0, dated 26 September 2025, restored PUL 2.0 as the primary endpoint and changed the measure to percent change. Version 3.0 followed on 24 November 2025. It redefined the baseline score and added the rule on prohibited medicines. The database was locked and unblinded the next day. So version 3.0 was signed 159 days after the last blinded visit and one day before unblinding (computed).
Capricor’s position
Capricor’s answer rests on the order of events. In a statement issued before the July advisory committee, it said version 3.0 was “finalized prior to unblinding”. Its briefing document says the move to percent change followed recent publications that treat it as a more sensitive measure of function. It also says the FDA reviewed version 1.7 and gave no further feedback. On this account every change was made blind, and the published result is the valid one.
The FDA’s position
The FDA’s reviewers did not dispute those dates. Their concern was who made the changes and what those people could have known. The trial’s blinding plan gave the analysis plan to an outside statistics firm with no access to treatment codes. Versions 2.0 and 3.0 were written by Capricor itself, according to the FDA document, and statistical programming had moved in-house in October 2023.
The reviewers also described a way the blind could leak without anyone opening a code. Hypersensitivity reactions occurred in 41.5% of patients on deramiocel and 15.4% of those on placebo. A reaction after an infusion is a strong hint about which arm a patient is in. The FDA calls this functional unblinding. Once the 12-month phase ended, every patient could move to open-label treatment, which widened that window.
A further point concerns the study report itself. Its analysis is dated 3 February 2026, which is 70 days after unblinding (computed). The FDA document says the model in it matched none of the written plans. In July these were concerns raised by reviewers. In November the FDA’s statement reports unauthorised post hoc changes and blinding violations as findings of its inspection.
What the public record shows
The trial’s registry entry still carries both versions of the endpoint. On 21 November 2026 its outcome field listed the primary measure as the mean percent change in PUL 2.0. Its detailed description, further down the same page, still gave the mean change from baseline.
The Lancet paper reports the percent-change analysis and says the authors knew of no incident that compromised masking. It appeared on 29 July 2026, the day the advisory committee met. Capricor funded the trial, and the paper’s authors include company staff.
HOPE-2, the earlier phase 2 trial, shows the same disagreement on a smaller scale. The 2022 Lancet paper (McDonald et al., via PubMed) reports a benefit on its primary endpoint, analysed as percentile ranks, with a P value of 0.014. The FDA document says the switch to percentile ranks came after unblinding and that the endpoint was missed under the original model. That trial stopped at 20 of a planned 84 patients.
05The heart data, the 9 to 3 vote and the indication switch
The application first asked for approval in cardiomyopathy, so the heart data mattered most at the start. They are also where the published figures disagree most. The table below lists every LVEF difference between the arms that Witfire found in the FDA and Capricor documents.
Under the first plan, LVEF fell by 0.95 points on deramiocel and 0.91 on placebo, which is no difference at all. Capricor’s later analysis ranked the patients. In a ranked analysis each patient’s change is replaced by his position in a list from worst to best, and the average positions are compared. Ranking resists distortion by extreme values, which is Capricor’s stated reason for using it. The FDA’s objection is that a gap of 11.65 ranks cannot be read as a change in heart function.
The two arms also began in different places. Mean LVEF at baseline was 59.3% on placebo and 55.3% on deramiocel, and all five patients with LVEF below 45% were in the deramiocel arm. That starting gap of four points is larger than any treatment difference either side reports (computed). A “nominal” P value, such as the one in the last row, is one that has not been adjusted for the number of comparisons made.
Missing scans add to the uncertainty. The ranked analysis used 83 of the 106 randomised patients. By the FDA’s count that left out 23, or 22%. The FDA’s committee slides note that Capricor’s analysis excluded six further patients with no month 12 scan, five of them on deramiocel. Three of those five had shown a fall in LVEF at month 6.
The advisory committee
On 29 July 2026 the FDA took one question to its Cellular, Tissue and Gene Therapies Advisory Committee. This is a panel of outside experts whose votes guide the agency without binding it. The question was whether HOPE-3 gave substantial evidence that deramiocel works for cardiomyopathy in DMD. Three members voted yes and nine voted no.
The switch to the arms
Capricor then changed course. In August it filed a major amendment with 24-month data from the open-label extension, in which every patient receives deramiocel. It also changed the use it was asking for, from cardiomyopathy to upper limb impairment in patients older than nine. The amendment moved the decision date from 22 August to 22 November.
That switch placed the whole application on the endpoint where the two analyses disagree. It also leaned on open-label data, in which patients and assessors know the treatment. The FDA document had already cautioned that PUL scores can be biased under those conditions. On 20 November the agency rejected the application as amended.
06Deramiocel mechanism of action: how the cells are thought to work
It is natural to assume that a cell therapy works by supplying new cells to a failing organ. Deramiocel is not thought to work that way. The Lancet paper says the cells survive for only one to two weeks after infusion. Capricor’s briefing document adds that they do not multiply or settle permanently in tissue. That short life is why the dose is repeated every three months.
The proposed benefit comes from what the cells release while they are alive. They give off proteins and exosomes. Exosomes are tiny membrane-bound packets that carry RNA and proteins from one cell to another. Biologists call this paracrine signalling, meaning a cell acting on its neighbours through the substances it secretes.
Two targets are named. The first is the immune system, where the signals are said to act on macrophages, a type of white blood cell, and to dampen inflammation. The second is the fibroblast, the cell that lays down collagen and builds scar tissue. In a 2025 laboratory study (Li et al., Biomedicines, via PubMed), fluid from more than 100 manufacturing lots lowered the activity of two collagen genes in fibroblasts. The effect disappeared when exosomes and soluble proteins were removed from the fluid.
That study explains how each lot is tested for potency, and all of its authors work at Capricor. It is evidence of an effect in a dish. The briefing document supports the wider mechanism mostly with animal studies. Whether the same chain of events slows muscle loss in patients is what HOPE-3 was meant to show, which returns the question to the disputed analysis.
Capricor makes the cells at its own facility in San Diego. HOPE-3 had two cohorts for that reason. The first received product made in Los Angeles. The second received product from San Diego, which the briefing document calls the commercial site.
07Deramiocel side effects in HOPE-3
According to the Lancet abstract, the safety profile was similar to placebo. The FDA’s document gives the counts by arm for the 105 patients who received at least one infusion, and they show one clear imbalance.
Hypersensitivity reactions were 2.7 times as frequent on deramiocel as on placebo (computed). They occurred even though every patient received a high-dose oral corticosteroid and an antihistamine before each infusion. Serious adverse events ran the other way, with five patients affected on placebo and one on deramiocel.
The single case of anaphylaxis, a severe allergic reaction, was in a placebo patient at his first infusion. The placebo contained every ingredient of the product except the cells. For that reason the FDA suggests the inactive ingredients may have played a part. One patient on deramiocel was suspected of an immune sensitisation syndrome.
The reaction rates matter twice. They are a tolerability cost for a therapy meant to be given for life. They are also the route by which the FDA thinks patients and staff could have guessed the treatment arm. The agency’s reviewers concluded that the balance of benefit and risk was unfavourable without reliable evidence of benefit.
08Capricor’s cash, its lease and the share price
Capricor has no product on sale, so its finances come down to how long its cash lasts. Its quarterly report gives the position at 30 September 2026. The release of 20 November quotes about $198.5 million, a figure that also counts restricted cash.
Months of cash at that rate $197.6M ÷ $10.7M = 18.4
Cash per share $197.6M ÷ 58.1M = $3.40
Market value at the close 58.1M × $7.59 = $441M
Market value after hours 58.1M × $1.63 = $95M
The news arrived after the market closed on Friday, so the first full session is Monday 23 November. In after-hours trading the shares changed hands near $1.63, a fall of about 79%, as GuruFocus also reported. At that price the stock market values the company below its cash. A discount of that kind usually means investors expect much of the cash to be spent before a product earns it back.
Capricor says its cash funds at least 12 months and that it is reviewing its costs. The simple division above gives about 18 months at the 2026 rate, before any cuts and before any new costs. The company’s last share sale was in December 2025, at $25.00 a share. A sale at Friday’s after-hours price would need about 15 times as many shares to raise the same money (computed).
A lease tied to approval
One commitment in the quarterly report now needs attention. On 9 July 2026 Capricor signed a lease for a new headquarters with base rent of about $958,000 a month, or $11.5 million a year (computed). The lease lets either party end it if deramiocel is not approved for DMD on acceptable terms by 31 December 2026. That date is 41 days after the CRL (computed), which is far less time than a resubmission takes to review. Whether Capricor or its landlord uses the clause is an open question.
The partner and the courts
Nippon Shinyaku of Japan (TYO: 4516) holds exclusive US distribution rights under a 2022 agreement and Japanese rights under a 2023 one. In May 2026 it filed a complaint seeking rescission, which would cancel the contract. The dispute has since moved to arbitration with claims on both sides. The quarterly report also lists securities class actions in California and a patent suit brought by Mesoblast (Nasdaq: MESO) in July 2026.
09What can happen next for deramiocel
A CRL closes one review and leaves the application open. Parent Project Muscular Dystrophy, the patient group, made the same point to families on 21 November. The routes from here are few, and each depends on what the unpublished letter says.
The first step is usually a Type A meeting, where the company and the FDA discuss what a new submission would need. Capricor has not said when it will ask for one. It can also reply to the Regulatory Responsibility Letter and contest the inspection findings. If the FDA holds to its view that the HOPE-3 data cannot be repaired, a resubmission built on those data has little to stand on. The statement stops short of saying that a new trial is required.
A new placebo-controlled trial would be the conventional answer, and it would be slow. HOPE-3 took almost three years from its first patient to its last blinded visit. Capricor would also have to fund it from a cash balance that covers about 18 months at the current rate.
Patients already on treatment
The registry record says patients who finish 24 months may continue in a long-term extension. That extension runs until the product is sold commercially, the sponsor ends the trial, or the patient withdraws. Parent Project Muscular Dystrophy says it is unclear whether access will continue and advises families to contact their study teams. Capricor’s quarterly report counts more than 1,300 infusions given to about 125 patients across its three DMD trials. The first of them was the open-label HOPE-Duchenne study (Taylor et al., Neurology 2019, via PubMed).
Other treatments
Parent Project Muscular Dystrophy lists eight therapies approved by the FDA specifically for Duchenne. They include corticosteroids, exon-skipping drugs for particular mutations, a histone deacetylase inhibitor and one gene therapy, Elevidys from Sarepta (Nasdaq: SRPT). The FDA has limited Elevidys to patients who can still walk, after fatal liver failure in non-ambulatory patients. About 85% of HOPE-3 patients could not walk. Older, non-ambulatory patients are the group with the fewest options, and they are the group deramiocel was tested in.
Witfire has covered two other FDA rejections this year with different causes. Unicycive’s CRL turned on manufacturing, and Replimune’s RP1 was refused despite a 34% response rate. Capricor’s case is a third kind, in which the FDA questions the reliability of the trial data.
10Deramiocel and India: no sites, a funding ceiling and a lesson for sponsors
None of HOPE-3’s 20 sites was in India. Every one was a US hospital, so no Indian patient has received deramiocel in the trial. Capricor’s release names regulatory designations in the United States and Europe only, and its partner’s rights cover the United States and Japan.
For Indian families the relevant framework is the National Policy for Rare Diseases, launched in 2021. The health ministry says the policy provides up to ₹50 lakh per patient for treatment at notified Centres of Excellence. Duchenne is on the list of notified conditions. An Outlook India report describes parents being told that the medicines cost more than that ceiling.
Deramiocel would test the ceiling in a particular way. It is made from donor hearts at one US facility and given four times a year for as long as it helps. A lifelong infused cell therapy is a recurring cost, unlike a one-time gene therapy. No price has been set, because the product is not approved anywhere.
The wider lesson is for Indian companies and contract research organisations that run trials for US filings. The FDA inspected the sponsor’s own handling of the analysis plan and the blind, as well as a hospital site. A trial can be clinically sound at every site and still fail if the statistics were not kept at arm’s length. Witfire has written about the scale of that work in its piece on India’s contract research sector.
Three habits follow from HOPE-3. The final analysis plan should be signed before the last patient’s last visit where possible. A statistician with no access to treatment codes should write it. Every later change should be dated, justified and filed with the regulator before unblinding.
11Witfire Risk Score: 7.2 / 10
This score covers the deramiocel programme as it stands after the second CRL and before Capricor has met the FDA.
12What to watch
- 23 November 2026, 8:30 a.m. Eastern. Capricor’s call (CAPR) and the first regular trading session since the CRL. The useful details are what the letter asks for and whether a new trial is named.
- The letters. Whether Capricor or the FDA releases the CRL or the Regulatory Responsibility Letter, and how the company answers the inspection findings.
- A Type A meeting request. Capricor has given no date. Its outcome will show whether any part of HOPE-3 can be used again.
- 31 December 2026. The approval date written into the headquarters lease. Either party may end the lease if the condition is not met.
- Early 2027. The annual report, with any cost cuts and any change to cash guidance. The registry lists March 2027 as HOPE-3’s completion date.
- Nippon Shinyaku (TYO: 4516). The arbitration over the US distribution agreement, and whether the partner cites the FDA’s statement.
- The published record. Any update to the registry’s endpoint text, and any note from The Lancet on the HOPE-3 paper.
HOPE-3 did not show that deramiocel fails. On the arm scale the treated patients declined a little less under every analysis. What the trial could not do is prove that the gap is real, because the answer depends on choices made after the blinded phase ended.
The plainest fact in the record is that two placebo patients separate P = 0.21 from P = 0.045. A result that rests on so little needs the cleanest possible process behind it. The FDA says the process fell short, and Capricor says every change was made blind. Only the unpublished letters can settle which account holds.
For families, the cost is time. The patients deramiocel was tested in have the fewest alternatives, and a repeat trial would take years. For the wider field, HOPE-3 is a clear teaching case. A modest effect and a plan that kept changing could not be told apart afterwards.
FAQDeramiocel: questions and answers
What is deramiocel?
Deramiocel, also called CAP-1002, is a cell therapy from Capricor Therapeutics for Duchenne muscular dystrophy. It is made of cardiosphere-derived cells grown from donated human hearts. In the phase 3 HOPE-3 trial patients received 150 million cells by intravenous infusion every three months. It is not approved in any country.
Is deramiocel FDA approved?
No. The FDA issued a Complete Response Letter on 20 November 2026, its second for this product. The first came in July 2025. A Complete Response Letter means the agency has finished its review and cannot approve the application as filed. Capricor can still meet the FDA and submit again.
Why did the FDA reject deramiocel?
Capricor says the letter found the evidence of effectiveness insufficient and cited other clinical deficiencies. The FDA’s own statement goes further. It says an inspection found unauthorised changes to the HOPE-3 statistical analysis plan, violations of blinding procedures and other protocol violations. The agency calls the trial’s data unreliable as a result. The letter itself has not been published.
Did the HOPE-3 trial meet its primary endpoint?
It depends on the analysis. Under the plan written in July 2022, the difference in upper limb score was 0.66 points with a P value of 0.24, which is not significant. Under the final analysis, which used percent change and later rules for two placebo patients, the difference was 4.55% with a P value of 0.029. Capricor and The Lancet report the second result. The FDA relies on the first.
What is a statistical analysis plan, and why does its timing matter?
A statistical analysis plan fixes how a trial’s data will be analysed before the results are known. If the plan changes after people can see which patients received the therapy, the changes may be shaped by the data. HOPE-3’s third plan is dated 24 November 2025, one day before unblinding and 159 days after the last blinded visit. Capricor says that timing keeps it valid. The FDA says the changes were unauthorised.
What is a BIMO inspection?
BIMO is the FDA’s Bioresearch Monitoring programme. Its inspectors visit trial sites, sponsors and contractors to check that a study followed its protocol and that the data are reliable. They list concerns on a Form 483. Capricor was inspected from 6 to 20 July 2026 and said its Form 483 carried one observation.
How does deramiocel work?
The cells are not thought to replace muscle. They survive for one to two weeks and release proteins and exosomes, which are small packets that carry signals between cells. These signals are said to dampen inflammation and reduce the collagen that forms scar tissue. Most of the supporting evidence comes from laboratory and animal studies.
What are the side effects of deramiocel?
In HOPE-3, hypersensitivity reactions occurred in 41.5% of patients on deramiocel and 15.4% on placebo, despite premedication with a corticosteroid and an antihistamine. Serious adverse events affected one patient on deramiocel and five on placebo. The one case of anaphylaxis was in a placebo patient.
Why did Capricor stock fall?
Capricor shares closed at $7.59 on Friday 20 November 2026 and traded near $1.63 after hours once the rejection was public, a fall of about 79%. The company held $197.6 million of cash and marketable securities at 30 September 2026. At the after-hours price its market value was about $95 million, or 48% of that cash (computed).
What happens to patients in the HOPE-3 extension study?
The registry record says patients may continue in a long-term open-label extension until the product is sold commercially, the sponsor ends the trial, or the patient withdraws. Parent Project Muscular Dystrophy says it is unclear whether access will continue and advises families to contact their study teams.
Is deramiocel available in India?
No. Deramiocel is not approved anywhere, and all 20 HOPE-3 sites were in the United States. India’s National Policy for Rare Diseases lists Duchenne and provides up to 50 lakh rupees per patient at notified Centres of Excellence.
Author. Dr. Akhilesh Vats is Editor-in-Chief of Witfire Elite and founder of ACME Research Solutions, a pharmaceutical contract research organisation.
Disclosure: Editorial analysis, not investment or medical advice. The Witfire Risk Score is our own framework, weighting Regulatory Exposure (30%), Competitive Displacement (25%), Capital Position (20%), Evidence Integrity (15%) and Execution & Credibility (10%) on a 1–10 scale. Scores are judgments, not forecasts.
Put this framework on your own file.
The same method used in these briefs, applied privately to a decision you are actually facing — a target, a partner, a facility, a filing.
- CMC & manufacturing risk assessment
- Regulatory / CRL readiness review
- Due diligence on a target or partner
- Investor brief or market analysis
- Commissioned editorial
- Something else
The signal before the market catches up.
A low-noise briefing on the pharma events that change strategy, risk and value. No more than one a week.
